ACKR1 rs2814778: The Duffy-Null Variant and Your Health
The rs2814778 variant in the ACKR1 gene is a promoter mutation that prevents the expression of the Duffy antigen on red blood cells. This genetic change is widely recognized for conferring resistance to Plasmodium vivax malaria and is associated with lower baseline neutrophil counts, a condition known as benign ethnic neutropenia.
What each genotype means
Duffy-null blood group
You carry two copies of the derived C allele, resulting in non-expression of the Duffy antigen on red blood cells (the erythrocyte-silent Duffy-null phenotype). This genotype provides strong natural resistance against erythrocyte invasion by the malaria parasite Plasmodium vivax. It is also strongly associated with naturally lower circulating absolute neutrophil counts (historically called benign ethnic neutropenia) without an increased risk of infection.
Carried by approximately 65% to 70% of African Americans and over 80% to 100% of populations in sub-Saharan West Africa, but virtually absent in European and East Asian ancestral populations.
Duffy-positive carrier
You carry one copy of the Duffy-null variant and one typical copy, which allows normal expression of Duffy antigens on your red blood cells. Individuals with this genotype generally have standard susceptibility to Plasmodium vivax infection compared to homozygous carriers. Peripheral neutrophil counts in heterozygous individuals are typically within conventional laboratory reference ranges.
Found primarily in admixed individuals with African or Arabian Peninsula ancestry, occurring in roughly 25% to 30% of African Americans.
Standard Duffy antigen expression
You carry two copies of the ancestral T allele, leading to standard expression of the ACKR1 chemokine receptor and Duffy antigens on erythrocytes. This genotype does not confer resistance to Plasmodium vivax malaria invasion. Circulating absolute neutrophil counts typically fall within standard population reference intervals.
Carried by over 99% of individuals of ancestral European and East Asian descent, while being relatively uncommon in sub-Saharan African populations.
Understanding the Variant
The variant rs2814778, often referred to as the Duffy-null allele, is a single nucleotide change located in the promoter region of the ACKR1 gene. This specific mutation, a T to C substitution at position -67, disrupts a critical binding site for the GATA1 transcription factor. Because this site is essential for the expression of the ACKR1 gene in erythroid cells (red blood cell precursors), the presence of this variant effectively silences the gene in those cells. Consequently, individuals who carry two copies of this variant do not produce the Duffy antigen on the surface of their red blood cells. This is a well-documented genetic mechanism that alters the surface profile of blood cells without affecting the overall function of the immune system or the health of the individual.
The Role of the ACKR1 Gene
The ACKR1 gene, formerly known as DARC (Duffy Antigen Receptor for Chemokines), encodes a protein that acts as a receptor for various chemokines—signaling proteins that help regulate immune cell movement. While the protein is expressed in several tissues, the rs2814778 variant specifically prevents its expression on red blood cells. This absence of the Duffy antigen on erythrocytes is the defining feature of the Duffy-null phenotype. Interestingly, while the protein is absent on red blood cells in these individuals, it remains expressed in other tissues, such as the endothelium. This tissue-specific regulation is why the Duffy-null status is considered a benign trait rather than a deficiency that impairs general immune function or systemic health.
Research and Clinical Associations
The most significant clinical association with the Duffy-null genotype is its role in malaria resistance. The Duffy antigen serves as a primary entry point for the parasite Plasmodium vivax to infect red blood cells; therefore, individuals lacking this antigen are largely protected against this specific form of malaria. Additionally, this variant is strongly associated with benign ethnic neutropenia (BEN). Individuals with the Duffy-null genotype often exhibit lower absolute neutrophil counts compared to those who express the antigen. Crucially, this lower count is considered 'benign' because it does not correlate with an increased risk of infection or immune dysfunction. Research emphasizes that these lower counts are a normal physiological variation for individuals with this genotype, rather than a sign of underlying disease or clinical neutropenia.
Population Frequency
The prevalence of the rs2814778 variant varies dramatically across global populations, largely due to historical evolutionary pressure from malaria. It is highly prevalent in populations of African ancestry, with frequencies often exceeding 80% in sub-Saharan African groups and approximately 65% in African American populations. In contrast, the variant is very rare in populations of European or East Asian descent, where the Duffy-positive phenotype is the norm. In some Middle Eastern populations, the frequency is intermediate, reflecting historical migration and admixture patterns. This distribution pattern is a classic example of natural selection, where a genetic variant that provides a survival advantage against a local infectious disease becomes fixed or highly common within that specific geographic region over many generations.
Interpreting Your Genetic Information
If you discover you carry the Duffy-null genotype, it is important to understand that this is a common, benign variation. It is not a disease, and it does not require medical treatment or lifestyle changes. However, if you are undergoing routine blood work, your clinician should be aware of your ancestry or genetic status, as standard reference ranges for neutrophil counts are often based on populations that are predominantly Duffy-positive. If your lab results show a lower-than-average neutrophil count, your doctor may interpret this in the context of your Duffy-null status to avoid unnecessary medical testing or concern. Always discuss any concerns regarding your blood counts or health markers with your primary care physician, who can provide context based on your complete medical history and clinical presentation.
How common is this variant?
The Duffy-null genotype (CC) is highly prevalent in individuals of African ancestry, often exceeding 80%, while it is very rare in European and East Asian populations.
Frequently asked questions
Is the Duffy-null genotype a health risk?
No, the Duffy-null genotype is not a health risk. It is a benign genetic variation that results in lower neutrophil counts, which do not increase the risk of infection.
Does being Duffy-null mean I cannot get malaria?
The Duffy-null genotype provides significant protection against Plasmodium vivax malaria. However, it does not provide protection against other types of malaria, such as Plasmodium falciparum.
Why do doctors sometimes worry about low neutrophil counts?
Doctors typically monitor low neutrophil counts because they can sometimes indicate an underlying infection or immune issue. However, in Duffy-null individuals, these counts are normal and expected.
Should I tell my doctor about my Duffy-null status?
Yes, it is helpful to inform your doctor if you know you are Duffy-null, especially if you are having blood tests. This helps them interpret your neutrophil counts correctly.
Sources & further reading
Educational information only, last refreshed 10/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2814779?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in ACKR1
This 'Duffy-null' variant is associated with benign ethnic neutropenia and an increased risk of clozapine-induced neutropenia, while providing protection against Plasmodium vivax malaria.
Provides resistance to Vivax malaria; common in those with African ancestry.